SecBot SecBot
Biotech Drug Report Generated Jul 1, 2026

ALX2004

ALXO·ALX ONCOLOGY HOLDINGS INC
NEUTRAL
Drug Impact Rating5/10
Trial phase
Phase 1
Time to market
At least 5-7 years if successful (currently in Phase 1 dose-escalation; typical ADC development timelines from Phase 1 to approval span 5-8 years)
Why 5/10
The next hard catalyst is the initial Phase 1 safety data readout from the dose-escalation trial (NCT07085091), expected in the second half of 2026. ALX2004 is the company's second pipeline asset behind lead CD47 blocker evorpacept, so this catalyst is meaningful for pipeline diversification but not a make-or-break binary for ALXO, which has cash runway through 1H 2028.
Actionable Insight NEUTRAL

Investors should watch for the Phase 1 safety data readout in 2H 2026, which will be the first clinical data for this program. Positive results could unlock a $10M contingent tranche from HSVC's $50M credit facility. The data will also validate ALXO's internal ADC platform and inform whether the drug can differentiate in a competitive EGFR-targeted ADC landscape where MRG003 (becotatug vedotin) was already approved in China in November 2025.

Price Chart

Loading chart...

Executive Summary

ALX2004 is ALX Oncology's second clinical-stage pipeline candidate, a novel EGFR-targeted antibody-drug conjugate (ADC) using a topoisomerase I inhibitor payload with a proprietary linker designed to minimize off-tumor skin toxicity. It entered Phase 1 clinical trials in August 2025 (NCT07085091) in EGFR-expressing solid tumors (NSCLC, HNSCC, ESCC, CRC). The dose-escalation has cleared two cohorts without DLTs, and initial safety data is expected in the second half of 2026. ALX2004 is the company's second program behind evorpacept (CD47 blocker), but represents important pipeline diversification and validation of ALXO's internal ADC platform. The EGFR-targeted ADC space is competitive, with MRG003 (becotatug vedotin) becoming the world's first approved EGFR ADC in China in November 2025.

How It Works

ALX2004 is an antibody-drug conjugate (ADC), a targeted cancer therapy that works like a guided missile. One part of the drug (the antibody) seeks out and binds to EGFR, a protein found on the surface of many cancer cells. The other part delivers a chemotherapy payload (a topoisomerase I inhibitor) directly inside the cancer cell to kill it. ALX2004 uses a proprietary linker designed to keep the payload stable in the bloodstream and release it only inside tumor cells, which could reduce side effects like skin toxicity seen with other EGFR-targeting drugs.

Trial Status

Phase 1 first-in-human dose-escalation trial (NCT07085091) is actively enrolling. First patient dosed August 2025. Dose cohorts at 1 mg/kg and 2 mg/kg cleared without dose-limiting toxicities; 4 mg/kg cohort currently enrolling. Initial safety data from the dose-escalation phase is anticipated in the second half of 2026 (was originally guided for H1 2026, then pushed to 2H 2026 as of the Q4 2025 earnings call in February 2026). The trial is enrolling patients with previously treated advanced/metastatic NSCLC, HNSCC, ESCC, and CRC.

The Two-Sided Case

▲ Bull Case6
Differentiated mechanism: ALX2004 uses a proprietary topoisomerase I inhibitor payload with a linker designed for improved stability and reduced skin toxicity, potentially overcoming the tolerability limitations that plagued earlier EGFR-targeted ADCs like depatux-m (AbbVie, which failed Phase III).
Strong preclinical data presented at AACR-NCI-EORTC 2025 showed superior bystander killing effect compared to deruxtecan-based ADCs, suggesting potential for activity in heterogeneous tumors.
Clear early safety signal: Dose escalation has progressed through 1 mg/kg and 2 mg/kg cohorts with no dose-limiting toxicities reported, and the 4 mg/kg cohort is enrolling, supporting the differentiated tolerability thesis.
Favorable company-level setup: ALXO has strong institutional support (RA Capital, Blackstone, Driehaus, RenTech all added positions in Q1 2026), $169.1M cash with runway through 1H 2028, and a $50M HSBC credit facility with a $10M tranche contingent on positive ALX2004 safety data.
Analyst consensus is bullish: 11 Buy ratings vs 2 Hold, mean price target $4.60 (151.6% implied upside from $2.07).
Large addressable market: EGFR is expressed in NSCLC, colorectal, head & neck, esophageal, and other common solid tumors, a multi-billion-dollar opportunity if the drug shows efficacy.
▼ Bear Case6
Very early stage: ALX2004 is in Phase 1 dose-escalation with no efficacy data yet, the vast majority of Phase 1 oncology assets never reach approval. Clinical data is still ~3-6 months away.
Crowded competitive landscape: The first EGFR-targeted ADC (MRG003/becotatug vedotin by Lepu Biopharma) was already approved in China in November 2025. There are 25+ companies and 30+ drugs in the EGFR NSCLC pipeline alone. Enhertu (HER2 ADC) has set a high bar for ADC expectations.
Pipeline lagging behind lead asset: ALX2004 is ALXO's second program; evorpacept (CD47 blocker) is the primary value driver. ALX2004 alone is unlikely to move the stock dramatically given the company's broader pipeline focus.
Equity dilution risk: Despite the recent $150M offering (Feb 2026), ALXO remains a pre-revenue clinical-stage biotech burning ~$17.9M per quarter (Q1 2026 net loss). Further equity raises could dilute shareholders.
Safety data delay: The initial safety readout was pushed from H1 2026 to H2 2026 (per Q4 2025 earnings), which may signal enrollment challenges or dose-finding complexity.
High volatility: Stock has a 52-week range of $0.41 to $2.66. HV30 of 84.73% indicates extreme volatility, making this a high-risk, high-reward position.

Upcoming Catalysts

  • Phase 1 ALX2004 initial safety data readout from dose-escalation, expected in 2H 2026 (likely Q3-Q4 2026)
  • Evorpacept (lead asset) pivotal ASPEN-09 Phase 2 data expected mid-2027, this is ALXO's primary near-term value catalyst
  • Potential $10M contingent tranche from HSBC credit facility tied to positive ALX2004 Phase 1 safety data
  • Jefferies Global Healthcare Conference participation (June/July 2026), pipeline updates

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALX ONCOLOGY HOLDINGS INC 8-K ALXO ·Originating report

Sources · 15

Hover a chip for the title
1 alxoncology.com2 biospace.com3 nasdaq.com4 fool.com5 ir.alxoncology.com6 fool.com7 targetedonc.com8 clinicaltrials.gov9 nasdaq.com10 egfrcancer.org11 globenewswire.com12 quiverquant.com13 sec.gov14 media.drugdu.com15 biospace.com